Profile data is unavailable for this security.
About the company
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
- Revenue in USD (TTM)2.62bn
- Net income in USD1.07bn
- Incorporated1996
- Employees1.17k
- LocationUnited Therapeutics Corp1000 SPRING STSILVER SPRING 20910United StatesUSA
- Phone+1 (301) 608-9292
- Fax+1 (301) 608-9291
- Websitehttps://www.unither.com/
More ▼
Mergers & acquisitions
| Acquired company | UTHR:NSQ since announced | Transaction value |
|---|---|---|
| IVIVA Medical Inc | 60.00% | 50.00m |
| Miromatrix Medical Inc | 61.02% | 139.42m |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tempus AI Inc | 595.57m | -790.20m | 8.40bn | 2.30k | -- | 85.49 | -- | 14.10 | -8.23 | -8.23 | 4.34 | 0.6367 | -- | -- | -- | -- | -- | -- | -- | -- | 51.85 | -- | -121.04 | -- | 3.52 | -28.75 | 0.8183 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 455.99m | -285.01m | 8.89bn | 2.20k | -- | 7.67 | -- | 19.49 | -1.57 | -1.57 | 2.51 | 6.33 | 0.2446 | 10.63 | 32.42 | 253,328.30 | -15.29 | -37.71 | -17.63 | -47.19 | 60.28 | -- | -62.50 | -286.51 | 4.78 | -16.63 | 0.2263 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.08bn | 431.79m | 10.63bn | 20.00k | 24.58 | 2.85 | 13.68 | 2.61 | 8.37 | 8.37 | 78.94 | 72.13 | 0.5188 | 8.23 | 5.22 | 203,888.80 | 5.67 | 6.46 | 6.52 | 7.62 | 35.98 | 36.99 | 10.93 | 11.58 | 1.21 | 4.97 | 0.39 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Medpace Holdings Inc | 2.03bn | 339.64m | 11.34bn | 5.80k | 34.39 | 14.81 | 30.82 | 5.58 | 10.63 | 10.63 | 63.59 | 24.69 | 1.22 | -- | 7.05 | 344,075.90 | 20.43 | 13.94 | 45.87 | 23.18 | 28.52 | 28.84 | 16.74 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Neurocrine Biosciences, Inc. | 2.12bn | 339.20m | 11.95bn | 1.50k | 35.74 | 4.76 | 32.84 | 5.64 | 3.31 | 3.31 | 20.64 | 24.87 | 0.7163 | 0.9811 | 4.95 | 1,513,929.00 | 11.46 | 9.77 | 13.74 | 12.19 | 98.28 | 98.51 | 16.00 | 14.79 | 4.08 | 6.10 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Sarepta Therapeutics Inc | 1.50bn | 47.30m | 12.13bn | 1.31k | 305.22 | 11.25 | 139.35 | 8.06 | 0.4168 | 0.4168 | 15.40 | 11.30 | 0.4595 | 0.4948 | 5.04 | 1,145,352.00 | 1.44 | -21.63 | 1.76 | -25.75 | 88.29 | 86.65 | 3.14 | -77.05 | 3.19 | -- | 0.5324 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| BIO-TECHNE Corp | 1.16bn | 168.07m | 12.42bn | 3.10k | 74.82 | 5.99 | 44.39 | 10.72 | 1.05 | 1.05 | 7.20 | 13.08 | 0.4339 | 2.22 | 5.04 | 373,890.30 | 6.29 | 9.42 | 6.65 | 10.04 | 66.41 | 67.29 | 14.50 | 21.41 | 2.75 | 13.32 | 0.1336 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
| Insmed Inc | 328.61m | -802.69m | 12.75bn | 912.00 | -- | 318.62 | -- | 38.81 | -5.40 | -5.40 | 2.22 | 0.2329 | 0.2023 | 0.8789 | 9.22 | 360,312.50 | -49.41 | -40.96 | -63.68 | -46.88 | 77.61 | 77.99 | -244.27 | -212.92 | 2.53 | -14.67 | 0.9687 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Exact Sciences Corp | 2.61bn | -175.01m | 12.95bn | 6.50k | -- | 4.05 | 337.50 | 4.96 | -0.9607 | -0.9607 | 14.28 | 17.29 | 0.401 | 5.43 | 11.81 | 401,847.80 | -2.69 | -9.71 | -2.95 | -10.60 | 73.19 | 74.10 | -6.70 | -28.21 | 1.98 | -- | 0.4478 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Vaxcyte Inc | 0.00 | -497.19m | 15.30bn | 254.00 | -- | 6.41 | -- | -- | -4.62 | -4.62 | 0.00 | 17.96 | 0.00 | -- | -- | 0.00 | -27.70 | -34.22 | -28.85 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| United Therapeutics Corporation | 2.62bn | 1.07bn | 15.71bn | 1.17k | 16.23 | 2.75 | 13.90 | 6.00 | 21.75 | 21.75 | 53.16 | 128.25 | 0.3904 | 2.43 | 9.29 | 2,240,325.00 | 15.96 | 10.38 | 17.53 | 11.27 | 88.85 | 91.47 | 40.87 | 29.25 | 4.18 | -- | 0.0807 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Summit Therapeutics Inc | 0.00 | -161.69m | 17.67bn | 105.00 | -- | 90.56 | -- | -- | -0.2299 | -0.2299 | 0.00 | 0.2693 | 0.00 | -- | -- | 0.00 | -55.83 | -77.32 | -75.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -51.01 | 0.3389 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
Data as of Sep 20 2024. Currency figures normalised to United Therapeutics Corp's reporting currency: US Dollar USD
52.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 4.38m | 9.84% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 4.36m | 9.79% |
| Avoro Capital Advisor LLCas of 30 Jun 2024 | 2.86m | 6.43% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 2.74m | 6.15% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.29m | 5.16% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 2.17m | 4.89% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Jun 2024 | 1.62m | 3.64% |
| Geode Capital Management LLCas of 30 Jun 2024 | 1.05m | 2.36% |
| LSV Asset Managementas of 30 Jun 2024 | 966.37k | 2.17% |
| AQR Capital Management LLCas of 30 Jun 2024 | 719.51k | 1.62% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
